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THE PREVALENCE OF GESTATIONAL DIABETES MELLITUS 
IN THE LATINX COMMUNITY  
NICOLE EVA HERNÁNDEZ 
ABSTRACT 
This literature-based thesis aimed to evaluate the relationship between gestational 
diabetes mellitus (GDM) and the Latinx community. The Latinx community is one of the 
groups most affected by GDM in the United States of America. Latinx patients have 
higher prepregnancy body mass index (BMI) and excessive gestational weight gain 
(GWG), the two main risk factors for developing GDM. The occurrence of GDM 
increases the risk for adverse pregnancy outcomes and early onset type II diabetes 
mellitus (T2DM) postpartum. For the fetus, GDM increases the risk of hypoglycemia and 
hyperinsulinemia, both of which can affect the long-term metabolic health. Current 
treatments of GDM in Latinx patients focus on lifestyle intervention through diet and 
exercise, an action that proves to be effective in this population. Enhanced GDM care that 
includes pregnancy health education in a group setting significantly improves birth 
outcomes. Advanced screening utilizing biomarkers and more accessible diagnostic tools 
is recommended for improving GDM treatment in Latinx patients. Finally, pregnancy 
studies on GDM should adequately represent the Latinx population among participants. 
Although this thesis analyzed GDM in the Latinx community and offered solutions for 
the disproportionate adverse pregnancy outcomes, these results may also be applicable to 
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This literature-based thesis aims to evaluate the relationship between gestational 
diabetes mellitus (GDM) and the Latinx community. The Latinx community is one of the 
groups most affected by GDM in the United States of America (U.S.). This analysis 
discusses the effects of GDM on maternal and fetal health. This thesis also explores the 
etiology of GDM as well as the long-term health outcomes with the goal of analyzing 
current treatment paradigms in the Latinx community. Further, this paper considers 
potential improvements in GDM treatment and management in the Latinx community 
and other communities disproportionately affected by GDM. 
For the purposes of this paper, the Latinx community describes patients of Latin 
American descent defined in papers as “Latino/a” or “Hispanic.” The term Latinx is a 
more inclusive way to describe persons of Latin American descent in a non-gendered 
fashion. The term “Hispanic” includes anyone who speaks the Spanish language, 
including persons of Spanish descent. In terms of medical research in the U.S., the 
grouping of Latinx persons based on health trends predominantly describes communities 
of Latin American descent and not European descent. Therefore, this analysis uses the 
term Latinx to discuss the effect of GDM on these pregnancies.  
 
What Is Gestational Diabetes Mellitus?  
About 10% of pregnancies in the United States are affected by GDM (American 
Diabetes Association [ADA], 2020). Gestational diabetes is defined as rapid glucose 
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intolerance and insulin resistance diagnosed for the first time in the patient during 
pregnancy (Chen et al., 2015). Regular prenatal care will screen for GDM because 
managing GDM can help avoid some of the associated adverse outcomes. Patients with 
GDM may present with glucose in the urine, unusual thirst, frequent urination, fatigue, 
and nausea (American Pregnancy Association, 2020). The prevalence of GDM in the 
U.S. warrants widespread screening for all pregnant patients, not just those exhibiting 
symptoms.  
Pregnancy causes the body to make several physiological changes, including 
some metabolic changes. Early in pregnancy, the body becomes more sensitive to insulin 
to promote glucose uptake in the adipose tissue in preparation for the energy demands 
present later in the term (Di Cianni et al., 2003). Afterward, a surge of placental 
hormones causes the body to shift to insulin resistance so that blood glucose levels rise 
and glucose is transported to the placenta (Catalano et al., 1991). The predominant 
placental hormone causing insulin resistance is placental lactogen (Parsons et al., 1992). 
This shift is necessary to meet the energy needs associated with the growth of the fetus 
and is considered a normal process in pregnancy. The pancreatic beta cells grow in size 
and number to balance the insulin resistance by having more sources of insulin 
production (Parsons et al., 1992).  
In GDM, normal insulin resistance in response to placental hormones is not 
counteracted by increased beta-cell function. GDM can be caused by beta-cell 
dysfunction in which the beta cells cannot adequately sense blood glucose levels or 
release sufficient insulin (Weir et al., 2001). In some cases, minimal beta-cell dysfunction 
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may have already been present to an extent but is only exposed by a metabolic stressor 
like pregnancy (Prentki & Nolan, 2006). Some cases of GDM are thought to potentially 
be undiagnosed type II diabetes mellitus (T2DM) or undiagnosed prediabetes. For 
younger patients there is the question of undiagnosed mature onset diabetes of the young 
(MODY). Also, beta-cell dysfunction can aggravate insulin resistance. If the beta cells 
cannot adequately respond to blood glucose levels, the normal state of insulin resistance 
during pregnancy becomes more severe as seen in GDM. Decreased insulin-stimulated 
glucose uptake requires the beta cells to release more insulin that can lead to beta-cell 
exhaustion (Ashcroft et al., 2017). Overproduction of insulin by the beta cells will cause 
the blood glucose signals to the beta cells to become dampened. Over time, the beta cells 
in a patient with GDM respond less efficiently to physiological signals, leading to 
increased insulin resistance compared with normal pregnancies.  
GDM also affects metabolism because of the associated chronic insulin 
resistance. When cells can no longer respond appropriately to insulin signaling, glucose 
transporter 4 (GLUT4) is unable to bring glucose into cells (Catalano, 2014). Increased 
phosphorylation of the insulin receptor can cause its signal to be dampened (Barbour et 
al., 2007). When the insulin receptor is phosphorylated, it can no longer bind its 
substrate, insulin receptor substrate 1 (IRS-1). Thus the signaling pathway that brings 
GLUT4 to the membrane is interrupted, and glucose will not be transported into cells. In 
GDM pregnancies, the response to insulin may be reduced by up to 54% compared with a 
regular pregnancy (Catalano, 2014). Figure 1 highlights how both beta-cell dysfunction 
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Beta-Cell Dysfunction and Chronic Insulin Resistance 
 
Note. This figure shows the pathophysiological differences between normal and GDM 
pregnancies. The images in the left column demonstrate how β-cells compensate for increased 
insulin resistance during pregnancy and how that compensation is inadequate in GDM 
pregnancies. The middle column highlights how blood glucose levels may be high even during a 
healthy pregnancy, but β-cell dysfunction leads to higher blood glucose levels in GDM. The right 
column demonstrates how the insulin receptor has a decreased response to high blood sugar 
leading to chronic insulin resistance in GDM pregnancies. GDM = gestational diabetes mellitus; 
IRS-1 = insulin receptor substrate 1. Adapted from (Plows et al., 2018).  
	
6 
GDM Diagnosis  
There are several ways to diagnose GDM, although some are considered better 
measures than others. The American Diabetes Association (ADA) has defined the 
standard of GDM diagnosis as a blood glucose level greater than 120 milligrams per 
deciliter 2 hours after a 75-gram glucose load, referred to as the 2-hour oral glucose 
tolerance test (OGTT) (ADA, 2020). The ADA also recommends that obstetricians 
confirm the diagnosis using another method for testing glucose tolerance if the 2-h OGTT 
result is abnormal. Other tests that can be done to diagnose GDM include the fasting 
plasma glucose (FPG) test, which measures the glucose level in plasma using a fasting 
blood analysis, and the 1-hour OGTT. The threshold values for a person who is not 
diabetic are 92 milligrams per deciliter for FPG and 180 milligrams per deciliter for 1-h 
OGTT (Metzger et al., 2010). In order for GDM to be diagnosed, at least one of the 
threshold values must be exceeded.  
Generally hemoglobin A1c (HbA1c) values are not used to diagnose GDM. 
Hemoglobin is found in red blood cells which have a lower life span during pregnancy, 
especially later in gestation. For this reason, HbA1c values are lower and change faster in 
pregnancy (Barquiel et al., 2016). The HbA1c value, however, is convenient in that it 
does not require fasting and can be performed during a routine blood analysis. Overall, 
the standard of care for testing for GDM is the 2-h OGTT, and other diabetes diagnostic 
tools can be used to confirm a GDM diagnosis.   
Because there is a narrow window for diagnosing GDM, widespread screening is 
important. GDM should be diagnosed between 24 and 28 weeks of gestation (Moore 
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Simas et al., 2019). Patients with GDM should be screened for T2DM, a known maternal 
complication of GDM, within six to twelve weeks postpartum as recommended by the 
American College of Obstetricians and Gynecologists (ACOG, 2009). As discussed later, 
the complications and long-term health effects of GDM are serious, so appropriate 
screening is imperative to prenatal care.  
  
Risk Factors for GDM 
Several risk factors are associated with the occurrence of GDM. The main 
associations studied are prepregnancy body mass index (BMI) and gestational weight 
gain (GWG). Prepregnancy BMI may be an increasingly important risk factor for GDM 
because about 60% of patients of reproductive age in the U.S. are obese or overweight 
(Flegal et al., 2010). Patients who are overweight or obese, as classified by BMI, are 
considered to be more at risk of developing GDM. For patients who have been pregnant 
before, failure to achieve their prepregnancy weight between pregnancies is also 
considered a risk factor, even if these patients are not technically overweight or obese 
according to their BMI (Chen et al., 2015). There are standardized guidelines for the 
appropriate GWG depending on prepregnancy BMI.  
The Institute of Medicine (IOM) set guidelines for GWG that were considered 
healthy in 1990. These guidelines were subsequently updated in 2009 (Institute of 
Medicine [IOM] & National Research Council [NRC], 2009). An update to the GWG 
guidelines was required as prepregnancy weight and maternal age have both increased in 
the United States over time. The 2009 study used to determine guidelines also aimed to 
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have more diverse participants, although the majority of participants were still White and 
non-Latinx. The authors of the recommendations even clarify in their limitations that 
there is insufficient evidence that these guidelines are suitable for patients of other racial 
or ethnic groups. This statement is pertinent considering that those groups are 
disproportionately affected by maternal morbidity and mortality. The guidelines also do 
not apply to pregnancies with multiple fetuses and adolescent pregnancies (IOM & NRC, 
2009).  
Changes made to the existing IOM GWG recommendations incorporated the 
World Health Organization (WHO) guidelines for BMI as shown in Table 1 (IOM & 
NRC, 2009). Furthermore, the 2009 update provided a more specific and narrow range of 
GWG guidelines for obese patients. Modern studies on GDM use the 2009 IOM 














2009 IOM Recommendations for Total and Rate of Weight Gain During Pregnancy, by 
Prepregnancy BMI 
Prepregnancy BMI Total weight gain Rate of weight gain in the 


















Normal (18.5-24.9 kg/m2)  11.5-16 25-35 0.35-0.5 0.8-1 
  
Overweight (25.0- 29.9 kg/m2) 
  
7-11.5 15-25 0.23-0.33 0.5-0.7 
Obese (≥ 30.0 kg/m2) 5-9 11-20 0.17-0.27 0.4-0.6 
  
 
Note. IOM = Institute of Medicine; BMI = body mass index. Adapted from (IOM & 
NRC, 2009).  
 
The most recent guidelines have already supported significant associations 
between prepregnancy BMI, GWG, GDM, and adverse health outcomes for the mother 
and fetus. Pregnancies in which the first trimester GWG exceeds the IOM 
recommendations are twice as likely to develop GDM (Moore Simas et al., 2019). The 
increased fat mass associated with the weight gain impairs the pregnant body’s ability to 
compensate for increased insulin resistance. Also, patients who were overweight before 
pregnancy and whose GWG exceeded standard guidelines were more likely to develop 
GDM than normal weight and obese subjects who also exceeded standard GWG 
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guidelines (Moore Simas et al., 2019). The metabolic profile of an obese person may 
explain why overweight patients have an increased risk of GDM. Obese patients may 
have prepregnancy insulin resistance that makes them less susceptible to a change in 
insulin resistance due to the metabolic stress of pregnancy; however, this change may be 
more notable in overweight patients. In addition, obese patients may be closer to 
exhausting beta-cell capacity than overweight patients, so GWG affects the metabolic 
profile of obese patients less (Moore Simas et al., 2019). Although pregnancies that begin 
overweight are more associated with GDM, obese prepregnancy BMI values may be a 
higher risk factor for other health outcomes.  
Pregnancies that begin at a higher BMI and develop GDM have several potential 
risks. The combination of GDM and obesity has a stronger association with adverse 
outcomes of pregnancy (Catalano et al., 2012). For this reason, physicians recommend 
reaching a normal weight BMI before conception. The relationship between obesity and 
GDM is even stronger for patients who gain excessive gestational weight during 
pregnancy than for patients with prepregnancy obesity (Catalano et al., 2012). This is the 
reason the IOM in 2009 narrowed the GWG for pregnancies that began at an obese BMI 
(IOM & NRC, 2009). Interestingly, one study found that the diet around the time of 
conception and in early pregnancy was not significantly associated with the onset of 
GDM (Yee et al., 2020). Prepregnancy weight and GWG both play important roles in the 
metabolic profile during pregnancy.  
Several factors besides prepregnancy BMI and GWG are associated with 
increased risk for developing GDM. For instance, the number of live births that a person 
	
11 
has had, or parity, is a risk factor for developing GDM (Vladutiu et al., 2016). The 
increased number of births is associated with an increased risk of developing GDM. 
Furthermore, a patient’s medical or familial history can make the individual more at risk 
of developing GDM. Patients with prediabetes before pregnancy are considered at risk 
for GDM. Multiparous patients with a history of GDM have a 30-69% chance of 
developing GDM in subsequent pregnancies (Chen et al., 2015). For patients who have 
developed GDM in a previous pregnancy, early screening can be a helpful tool for 
managing glycemic control. Diabetes is generally considered to have strong heritability; 
thus a family history of diabetes is a risk factor for GDM.  
Although no family studies have been conducted, certain individual traits can 
genetically predispose patients to GDM. For instance, genetic determinants of glucose 
and insulin levels may affect the likelihood of developing GDM. Genes like hepatocyte 
nuclear factor 1 alpha (HNF1A) and glucokinase (GCK) have polymorphisms that may 
determine the development of diabetes or GDM during pregnancy (Chen et al., 2015). 
Further studies classified biomarkers and genetic polymorphisms that are associated with 
GDM and the development of T2DM within five years postpartum (Khan et al., 2019). 
Identifying these risk factors early on in pregnancy is important for the screening and 
management of GDM. 
  
GDM Treatment 
GDM is treated by lifestyle intervention first and pharmacological options as 
needed. Generally, physicians try to achieve glycemic control by suggesting changes to a 
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GDM patient’s diet and exercise (González-Quintero et al., 2008). Patients newly 
diagnosed with GDM will be put on a diabetic diet. The suggested diet focuses on small, 
frequent meals with low to moderate carbohydrate content. Timing of meals is important. 
For instance, fruits are not recommended as part of breakfast, but they are suggested in 
moderation later in the day because of their high fiber content (González-Quintero et al., 
2008). Fruit juice and similar foods that have high sugar content should be avoided. 
Regular physical activity should also be implemented with lifestyle changes. The 
recommendation for patients with GDM is 30 minutes of walking five times a week in 
hopes of achieving glycemic control (González-Quintero et al., 2008). Lifestyle 
intervention may vary from patient to patient depending on the person’s prepregnancy 
habits.  
While lifestyle changes are being implemented, patients with GDM may be asked 
to self-monitor their blood glucose levels and report back to their physician. Often 
patients will be tasked with taking a fasting blood glucose measurement before breakfast 
and a two-hour postprandial blood glucose measurement following a meal (González-
Quintero et al., 2008). If self-reported blood glucose levels are not within a desirable 
range, the patients may be prescribed either an oral medication, like metformin, or insulin 
by their physician.  
Several benefits of treating GDM pregnancies with insulin have been studied. 
Most notable are the associations between insulin use and lower GWG in GDM patients 
(Hartling et al., 2013). As previously discussed, GWG can be a crucial determinant of 
maternal and fetal health outcomes, so insulin is appropriately used in GDM patients at 
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high risk for adverse outcomes. Insulin use in GDM pregnancies is also associated with 
lower rates of preeclampsia, although preeclampsia is not one of the major risks 
associated with GDM (Hartling et al., 2013). More important for fetal health, insulin 
treatment for GDM is associated with lower birth weights even though no long-term fetal 
benefits have been supported (Hartling et al., 2013). Some animal studies even support 
the use of drugs like metformin during lactation because associations have been noted 
with decreased adiposity and increased resistance to metabolic stressors in the fetuses 
(Carlson et al., 2020). Overall, there are several benefits to treating GDM during 






This thesis aims to study the prevalence of GDM in the Latinx community and to 
determine the best means to screen and manage the metabolic condition. These specific 
aims will be accomplished through the following objectives: 
1. To review current literature to characterize the nature of GDM and its prevalence 
in the Latinx community. 
2. To investigate the apparent causes for the high prevalence of GDM within the 
Latinx community.  
3. To investigate the long-term effects of GDM on maternal and fetal health. 
4. To evaluate the efficacy of current strategies for GDM prevention, screening, and 
management. 
5. To identify advancements in prevention, screening, and management specific to 





PUBLISHED STUDIES  
 
Gestational diabetes mellitus affects the Latinx population more than non-Latinx 
White pregnancies. One study found that there is a 12.1% occurrence of GDM in Latinx 
populations compared with non-Latinx White counterparts having a 6.8% occurrence 
(DeSisto, 2014). As seen in Figure 2, the age-adjusted prevalence of GDM in the Latinx 
community was higher than in non-Latinx White populations regardless of country of 
origin (Hedderson et al., 2010).  
As seen in Figure 2, even U.S.-born Latinx pregnant patients are at a higher risk 
of developing GDM than other groups. The prevalence of GDM in Latinx pregnancies 
places the Latinx community among the most affected racial or ethnic groups. Of all 
patients with GDM, Latinx patients are also more likely to develop T2DM postpartum 
(Gubrium et al., 2019). Because of the disproportionate burden GDM places on Latinx 
pregnancies, any study of GDM management and treatment should include Latinx 
subjects and should consider what genetic or sociocultural factors make Latinx 











Age-Adjusted GDM Prevalence by Race/Ethnic Group 
Note. This figure shows the percentage of pregnancies affected by GDM based on 
racial/ethnic group. The results indicate the differences among groups and between 
groups for subjects of the same racial/ethnic group but differing country of origin. The 
data were adjusted for maternal age. The Black racial group does not include Black 
Latinx subjects. GDM = gestational diabetes mellitus. Adapted from (Hedderson et al., 
2010).  
 
Suggested Causes of GDM in the Latinx Community 
Gestational diabetes mellitus is the subject of investigation for many researchers 
concerned with the health of mother and fetus, especially in groups in which GDM is 
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prevalent. Studies have shown that Latinx patients on average have a higher 
prepregnancy BMI compared with White patients (Carolan-Olah et al., 2017). Lower 
socioeconomic status (SES) and less nutrition education may lead Latinx individuals to 
consume more calorie-dense foods that contribute to a higher BMI (Carolan-Olah et al., 
2017). As previously mentioned, prepregnancy BMI is one of the most strongly 
associated risk factors for GDM. A higher BMI paired with increased GWG is a risk 
factor for GDM (Moore Simas et al., 2019). This finding was supported for U.S.-born 
Latinx subjects in a different study, although immigrant Latinx subjects did not have a 
significant association with GWG (Janevic et al., 2018). Differences between U.S.-born 
and immigrant Latinx pregnancies are not generally considered, but this discrepancy 
suggests that social determinants of health may also be responsible for the prevalence of 
GDM in Latinx pregnancies. Even though this thesis does not explore differences 
between U.S.-born and immigrant Latinx populations, it is an important avenue for 
further pregnancy research.  
GWG guidelines by the IOM subdivide classes of obesity from less severe, class 
I, to more severe, class III. These subdivisions are important for biomedical research 
because of differences in the metabolic profiles associated with the different levels of 
obesity. For instance, patients with class III obesity may not require any GWG for a 
healthy pregnancy (Zheng et al., 2019). These clinical findings are the basis of the 2009 
revision of GWG guidelines that offered a narrower range of appropriate GWG for 
patients with an obese prepregnancy BMI (IOM & NRC, 2009). Overall, GWG 
guidelines are an important factor of pregnancy health education. For instance, for each 5 
	
18 
kilograms gained during pregnancy, the odds of GDM increase by 1.13, and excess GWG 
increases the odds of GDM development by 68% (Zheng et al., 2019). Therefore, 
appropriate GWG is key for reducing risks of GDM development.  
Another risk factor for GDM is increased parity. Parity is a term that describes the 
number of prior live births, not pregnancies, which a patient has had. In general, the 
Latinx community is the ethnic group with the largest number of persons who can 
become pregnant in the United States. Also, Latinx families have higher birth rates 
compared with non-Latinx White families (Moore Simas et al., 2019). Both these factors 
lead to increased parity in the Latinx community compared with other racial or ethnic 
groups. Latinx patients average a higher prepregnancy BMI and increased parity. Studies 
have shown that increased parity is positively correlated with the occurrence of GDM 
(Vladutiu et al., 2016). The higher number of prior live births in Latinx pregnancies 
increases the risk for GDM, especially when considering that prepregnancy BMI is also 
generally higher.  
Some studies even show that Latinx patients may have a genetic predisposition 
for developing GDM. There is strong evidence to support the heritability of GDM. 
Namely, GDM pregnancies have significantly higher rates of parental history of T2DM 
compared with non-GDM pregnancies (Jang et al., 1998). However, it is important to 
note that no family studies have evaluated the extent of genetic influence in the 
development of GDM through twin studies. Some genetic variants that affect insulin or 
glucose concentration, like HNF1A or GCK, respectively, are also associated in patients 
with GDM (Chen et al., 2015). The HNF1A gene is responsible for beta-cell 
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development, and variants associated with diabetes, specifically MODY and GDM, are 
related to beta-cell dysfunction (Rosik et al., 2020). GCK variants, specifically 
Rs1799884, are strongly associated with GDM as supported by several large-scale studies 
(Chiefari et al., 2017). Although studies have yet to look at these genetic variants 
specifically in the Latinx community, the relevance of these polymorphisms makes them 
important risk factors for GDM. 
Overall, Latinx patients have higher rates of several risk factors associated with 
GDM. Whereas most studies show that Latinx and Asian patients have the highest 
occurrences of GDM, a systematic review of GDM by ethnicity and race also found that 
those subgroups are screened at a rate of 10% more than other patients (Herrick et al., 
2020). For instance, 45% of Latinx patients and 50% of Asian patients were screened for 
GDM by their obstetrician and gynecologist (OBGYN) compared with 35% of White 
patients and 33% of Black patients (Herrick et al., 2020). However, even studies in which 
other racial or ethnic groups are overrepresented, like Black patients in a Missouri study 
on pregnancies covered by Medicaid, the results still support the disproportionate effect 
of GDM on Latinx and Asian pregnancies (Herrick et al., 2019). The effectiveness of 
clinical GDM standards of care for treating one of the most affected groups, Latinx 
pregnancies, needs to be explored. Evaluation of the prevalence of GDM in the Latinx 
community is important because of the lasting effects that GDM can have on the health 




Maternal and Fetal Outcomes  
Gestational diabetes can have long-term effects on the postpartum metabolic 
profiles of the mother and fetus. One of the major risks of GDM for the mother is 
recurrence in subsequent pregnancies. Latinx pregnancies are more likely to have GDM 
recurrence (Carolan-Olah et al., 2017). GDM is also associated with hypertension and 
unplanned cesarean section later in the pregnancy (Carolan-Olah et al., 2017). Recurrence 
of GDM can eventually lead to the development of T2DM. For this reason, ACOG 
recommends screening for T2DM in GDM patients within six to twelve weeks 
postpartum (ACOG, 2009). The hope is that early screening and treatment will lead to 
better glycemic control in the long term. Almost half of the patients with GDM will 
develop T2DM within five to ten years postpartum (Khan et al., 2019). Considering that 
GDM affects a significant portion of Latinx pregnancies, this situation is increasing the 
number of diabetic Latinx adults. GDM poses a particular threat to maternal health 
because these patients will develop T2DM at a younger age, a condition called MODY, 
and therefore be at a greater risk of experiencing complications from diabetes in their 
lifetime.  
During pregnancy, GDM is associated with poor fetal development and adverse 
birth outcomes. The main concern for GDM pregnancies is maintenance of glycemic 
control. Increased maternal blood sugar is correlated with neonatal hypoglycemia (Chen 
et al., 2015). When the mother is unable to maintain glycemic control, blood sugar levels 
are high as glucose remains in the bloodstream and less glucose enters the cells. The less 
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glucose that is available in the cells, the less glucose that can be provided to the fetus by 
means of the placenta. This causes the fetus to become hypoglycemic. Hypoglycemia is 
considered dangerous and can affect the long-term health of the fetus. 
Many of the complications of GDM in the fetus are related to maternal 
hyperglycemia. The Pedersen hypothesis states that increased maternal glucose levels are 
associated with increases in fetal growth, adiposity, and concentrations of connecting 
peptide (C-peptide) (Pedersen, 1971). More recently, the Hyperglycemia and Adverse 
Pregnancy Outcome (HAPO) study supported the linear relationship of the variables in 
the Pedersen hypothesis (Catalano et al., 2012). However, the HAPO Study found that 
the Pedersen hypothesis also applies to overweight patients who might not have clinically 
diagnosed GDM but still have higher glucose profiles leading to the same adverse events. 
The relationship between maternal glucose levels and adverse pregnancy outcomes may 
be caused by the increase in concentration of lipids and amino acids that are noted during 
GDM pregnancies and have been associated with insulin resistance (Catalano et al., 
2012). Studies like the HAPO Study aim to apply what is known about GDM to the 
current U.S. population in the face of increasing prepregnancy BMI and maternal age.  
Many complications of fetal hypoglycemia have been studied. Postpartum, the 
infant is at increased risk of macrosomia (large size and birth weight), respiratory 
distress, obesity, early onset T2DM, and cardiovascular disease (Carolan-Olah et al., 
2017). Studies have suggested that GDM can affect the metabolic programming of the 
fetus so that adverse effects of GDM have lasting implications.  
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Glycemic control and weight management throughout a GDM pregnancy are 
important for fetal health. Studies have shown that HbA1c levels greater than five percent 
and GWG above IOM recommendations increase the rates of large for gestational age 
(LGA) birth weight and neonatal complications (Barquiel et al., 2016). In this study, 
LGA birth weight was defined as infant weight higher than the 90th percentile for 
gestational age. LGA birth weight is considered to be an important predictor for the 
cardiometabolic profile for life; therefore, GDM can have long-term effects on the health 
of the fetus. This study found significant differences in LGA rates and neonatal 
complications for both high HbA1c values and excess GWG when the groups were 
considered independently. The study also found that one-third of complicated births, 
including LGA and other complications, were prevented in pregnancies in which the 
average HbA1c was maintained below five percent after the GDM diagnosis (Barquiel et 
al., 2016). Similarly, 52% of LGA birth weights and 37% of other neonatal complications 
were prevented when GWG was within IOM recommendations (Barquiel et al., 2016). 
These findings reiterate the importance of achieving glycemic control, especially in GDM 
pregnancies. 
Although the IOM guidelines are specific to pregnancy, adequate GWG may not 
be the solution for patients with GDM. Overall, each kilogram gained during the third 
trimester increases the risk of LGA in GDM pregnancies by 10% (Mastella et al., 2018). 
Aside from LGA birth weights, increased fetal adiposity is also a known adverse outcome 
of GDM pregnancies. Some studies have proved that increased concentrations of lipids 
during pregnancy can lead to a gradual accumulation of fat in the fetus (Catalano & 
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Hauguel-De Mouzon, 2011). This finding is important because of the increased 
occurrence of prepregnancy obesity and the related increase in fetal adiposity. Studies 
have yet to determine the long-term effects that increased fetal adiposity may have on the 
health of the fetus.  
Another adverse outcome of GDM is fetal hyperinsulinemia. After delivery, blood 
is collected from the umbilical cord to measure the concentration of serum C-peptide 
(Catalano et al., 2012). A serum C-peptide concentration higher than 1.7 micrograms per 
liter is considered hyperinsulinemia. High levels of insulin can cause the neonate to 
become hypoglycemic, a dangerous condition, especially in combination with the other 
complication of GDM. The measure of serum C-peptide is important because it allows 
physicians to analyze the fetal beta-cell function (Catalano et al., 2012). The 
hyperinsulinemia at birth may be the cause of beta-cell dysfunction or exhaustion that 
leads to metabolic profiles associated with diabetes later in life.  
According to the Pedersen hypothesis, many fetal adverse outcomes from GDM 
pregnancies can be explained by fetal hyperinsulinemia caused by maternal 
hyperglycemia (Pedersen, 1971). When maternal glucose is high, insulin levels in the 
fetus will also rise if the beta cells are functioning properly. Insulin is the main growth 
factor for fetuses, so fetal hyperinsulinemia will cause increased fetal growth and 
adiposity (Mitanchez, 2010). Insulin has a trophic effect on several tissues. Insulin 
stimulates the intake and use of nutrients in adipose tissues and interacts with insulin-like 
growth factor (IGF) to stimulate the production of IGF-1 (Mitanchez, 2010). Macrosomia 
caused by fetal hyperinsulinemia can lead to other complications, namely, organomegaly. 
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The most common occurrence of organomegaly in fetuses of diabetic mothers is 
cardiomegaly (Mitanchez, 2010). Cardiomegaly is considered one of the predominant 
adverse outcomes of GDM and can have lasting effects on the cardiac health of the fetus. 
Macrosomia may also increase the risk of respiratory distress (Mitanchez, 2010). Cardiac 
and respiratory difficulties in a neonate can lead to lengthy hospital stays postpartum and 
eventual chronic health issues. The occurrence of GDM during pregnancy can have long-
term metabolic effects on the mother and fetus.  
 
Lifestyle Intervention 
Current methods of treating GDM focus on achieving glycemic control during 
pregnancy and preventing the development of T2DM postpartum. The first step in 
treatment is often lifestyle intervention, consisting mostly of changes in diet and physical 
activity. Studies have shown that diabetes education and regular follow-up with a medical 
professional can help patients control their GDM (González-Quintero et al., 2008). The 
majority of patients who performed daily fasting blood glucose, two-hour postprandial 
glucose, and ketone urinalysis testing and reported results to a diabetes educator were 
able to obtain glycemic control (González-Quintero et al., 2008). This study supported 
existing evidence that working with a certified diabetes health educator helps GDM 
patients achieve and maintain glycemic control later in their pregnancy. However, this 
study involved very frequent medical attention which is not currently the standard for 
most groups affected by GDM.  
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The efficacy of lifestyle intervention also varies by racial and ethnic group. 
Particularly in Latinx pregnancies, patients who received lifestyle intervention had 
significantly lower rates of T2DM development postpartum (Herrick et al., 2020). 
Patients who were not able to maintain glycemic control from this intensive lifestyle 
intervention had higher HbA1c values at GDM diagnosis and required pharmacological 
intervention within two weeks of diagnosis (González-Quintero et al., 2008). Although 
HbA1c values are not generally used diagnostically during pregnancy because of their 
low sensitivity, this data could help physicians predict which GDM patients will require 
more than just lifestyle intervention.  
Lifestyle intervention often involves health educators and can occur in a group 
setting. A survey of health educators working with GDM patients revealed that 
longitudinal support from intervention staff and shared cultural backgrounds are the most 
important tools currently used in GDM management (Gubrium et al., 2019). Health 
educators emphasized the importance of working with GDM patients over time to build 
an open and honest relationship that allows patients to more accurately describe their 
lifestyle and adherence to the doctor’s recommendations. Participants indicated that the 
longitudinal nature of most GDM lifestyle interventions gives health educators a clearer 
image of the patient’s life and what changes the patient can make to increase the chances 
of achieving glycemic control. Health educators in the study also noted that they felt 
having a shared cultural background helped them relate to the patients more and 
understand their lifestyle better (Gubrium et al., 2019). Currently, efforts are made to 
provide Latinx patients with lifestyle intervention strategies when diagnosed with GDM.  
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Diet is a main component of GDM lifestyle intervention, but exercise is often 
emphasized as well. Most recommendations include traditional exercise like walking. 
One study also created a system of metabolically equivalent task (MET) hours for 
activities of daily living (Nobles et al., 2018). Light and moderate household work like 
cleaning and childcare were assigned MET hours equivalent to time spent doing 
traditional exercise for physicians to better understand the lifestyle of the patient. Other 
behaviors may be taken into consideration in lifestyle intervention programs. For 
instance, risky behaviors like smoking are not recommended for patients with GDM 
(Nobles et al., 2018). Studies have found that most patients engage in at least one risky 
behavior. When considering modifiable behaviors, SES can be an important predictor of 
GDM development. Patients with low incomes are three times more likely to have a more 
sedentary lifestyle and engage in at least one risky behavior (Nobles et al., 2018). Any 
type of behavior modification must be realistic given the patient’s prepregnancy lifestyle 
in order to increase chances of achieving glycemic control.  
When lifestyle intervention is not sufficient for maintaining glycemic control, 
pharmacological agents may be used to treat GDM. Patients are most often prescribed 
either metformin or insulin to manage their GDM. More recent studies have proved many 
benefits to pharmacological treatment of GDM. For instance, there is a correlation 
between insulin use and lower GWG which can decrease the risk of some of the GDM-
related pregnancy complications (Hartling et al., 2013). This finding suggests that 
pharmacological intervention may be necessary in patients with narrower ranges of 
GWG, like obese patients. Also, in patients with GDM, the use of insulin is associated 
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with decreased recurrence of GDM in later pregnancies (Chen et al., 2015). These 
benefits explain why modern GDM management is beginning to rely on pharmacological 
interventions.  
With GDM, preventative efforts may be crucial to mitigating adverse pregnancy 
outcomes. Patients at risk for GDM not only have to be screened for GDM in the first 
trimester but also should be screened for T2DM within six to twelve weeks postpartum 
(ACOG, 2009). Currently, postpartum screening rates for T2DM are low, especially if 
only considering the recommended OGTT as standard (Hale et al., 2012). Because the 
OGTT requires the patient to fast for at least 8 hours prior to the test, the use of the 
diagnostic is limited if patients do not know to fast before their appointment. For many 
patients, postpartum care and screening are less likely if insurance coverage is irregular 
or insufficient. One study found a positive correlation between steady insurance coverage 
and postpartum screening for T2DM (McWilliams, 2009). This result suggests that 
patients with lower incomes, relying on programs like Medicaid, can be expected to have 
lower screening rates.  
In fact, when considering only the recommended OGTT test, as few as 3.4% of 
Medicaid patients diagnosed with GDM receive postpartum screening for T2DM within 
the recommended window (Hale et al., 2012). The number of patients screened increases 
slightly when other diagnostics like HbA1c values and finger sticks, or rapid glucose 
tests, are used (Hale et al., 2012). Overall, postpartum T2DM screening rates for GDM 
patients insured by Medicaid are lower than GDM patients with private insurance 
(Herrick et al., 2019). Postpartum screening rates for T2DM in GDM patients with 
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Medicaid may be so low because some patients will have Medicaid coverage only during 
pregnancy and 60 days postpartum (Markus & Rosenbaum, 2010). This insurance time 
frame limits the screening window for T2DM even further. Studies on the low screening 
rates of Medicaid patients postpartum are illuminating because Medicaid is the primary 





Despite  the novel treatments mentioned in the previous sections, Latinx 
pregnancies are disproportionately affected by GDM. As maternal age and prepregnancy 
BMI increase, GDM becomes a more common complication of pregnancy (IOM & NRC, 
2009). Given this trend, the groups most affected by GDM will be even more burdened. 
For this reason, advancements in prevention, screening, and treatment should focus on 
groups most affected by GDM like the Latinx community.  
  
Prevention and Screening 
The prevention of GDM in the Latinx community requires that the risk factors 
previously mentioned must be minimized. For instance, studies have shown that the 
implementation of diet and exercise programs in addition to standard prenatal care can 
moderately decrease the occurrence of GDM and cesarean section (Shepherd et al., 
2017). Participation in the diet and exercise programs was correlated with lower GWG, 
one of the most influential factors for the development of GDM. Preventing GDM may 
be especially important in patients who have had GDM in a previous pregnancy. Latinx 
patients run a higher risk of GDM recurrence in subsequent pregnancies (Carolan-Olah et 
al., 2017). However, it is important to note that although a healthy diet and regular 
exercise can reduce the occurrence of GDM and lower GWG, there is no significant 
difference in glycemic control (Simmons et al., 2017). This finding echoes the 
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suggestions of physicians that patients should try to decrease their risk factors through 
lifestyle intervention before trying to conceive.  
Even though there is a limited scope to GDM prevention, improved and precise 
screening could lead to earlier intervention that helps patients better maintain glycemic 
control. Diabetes screening should be performed at the first prenatal care visit to identify 
patients with prepregnancy diabetes that may not have been previously diagnosed 
(Metzger et al., 2010). Prepregnancy diabetes is associated with different risks than 
GDM, so proper diagnosis can be a critical component of care. Because prepregnancy 
diabetes is correlated with congenital abnormalities, the precautions taken for GDM may 
not be sufficient to treat those patients (Metzger et al., 2010). Overall, early diabetes 
screening can help identify patients who truly have GDM and not an undiagnosed 
metabolic condition.  
In terms of screening for GDM, biomarkers offer a promising solution to an early 
and precise diagnosis. Currently, there are several microRNAs that are proved to be at a 
higher concentration in the plasma for GDM pregnancies compared with non-GDM 
pregnancies (Cao et al., 2017). Other biomarkers that can be used to test for GDM are 8-
oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) and 8-hydroxy-2′-deoxyguanosine (8-
OHdG) (Urbaniak et al., 2020).  These two biomarkers are derivatives of guanine that are 
produced from the oxidative stress of metabolic pathologies like GDM. In addition, lipid 
signatures can be used to predict the development of GDM, particularly in Latinx and 
Asian pregnancies. There is an 83.6% accuracy in predicting the development of T2DM 
based on phosphatidylethanolamine (PE), phosphatidylserine (PS), and cholesteryl ester 
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(CE) patterns when considering other risk factors like BMI and history of GDM (Khan et 
al., 2019). The discovery of these predictive lipid signatures provides more support for 
genetic testing to determine the likelihood of GDM development during pregnancy and 
T2DM development postpartum.  
Some biomarkers even offer insight into the pathophysiology of GDM that is 
helpful for treatment and screening for T2DM. Several studies have shown that lipid 
imbalances, due to differences in biosynthesis and metabolism, are associated with beta-
cell dysfunction which causes diabetes (Khan et al., 2019). In patients diagnosed with 
GDM, sphingolipid metabolism downregulation is an early step in the development of 
T2DM postpartum. In vivo studies that inhibit sphingolipid metabolism noted a change in 
insulin sensitivity as gluconeogenesis is high and hepatic glucose uptake is hindered 
(Khan et al., 2019). This result is suggested as a partial cause of long-term glucose 
intolerance because of Akt (protein kinase B) phosphorylation of insulin receptors in the 
liver. Also, sphingolipid patches on beta cells are predictors of the functional capacity of 
the cell; therefore, an overall downregulation in lipid metabolism will likely affect the 
ability of the beta cells to maintain glucose levels (Khan et al., 2019). Although these 
findings are aimed at screening for T2DM, they could be helpful predictors for the 
development of GDM early on in pregnancy.  
To better improve the maternal health outcomes of GDM patients, T2DM 
screening postpartum should also be improved. Postpartum screening rates among low-
income and racially or ethnically diverse patients are generally low (Hale et al., 2012). 
Even though there are several social factors that can affect access to healthcare for these 
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patient populations, there are also measures that can increase screening. For instance, a 
positive association exists between patients who receive diabetes health education after 
GDM diagnosis and postpartum screening for T2DM (Hale et al., 2012). Patient 
education on the postpartum, long-term health effects of GDM may cause patients to seek 
T2DM screening or ask their provider for the appropriate tests.  
Offering simpler clinical solutions to low GDM screening rates may also help 
identify GDM patients earlier in pregnancy. To increase overall screening rates, the 
International Association of Diabetes and Pregnancy supports the use of readily available 
measurements like FPG and HbA1c for initial and broad screening of patients who may 
be at risk for GDM (Metzger et al., 2010). Both these tests are more common as part of a 
routine visit to the doctor. The convenience of these diagnostic tests makes them a 
solution for identifying which patients may need a 2-h OGTT. The International 
Association of Diabetes and Pregnancy recommends this two-phase approach to GDM 
screening so more patients can be screened for hyperglycemia in pregnancy (Metzger et 
al., 2010). With increased overall screening, the expected result is that more patients who 
need a 2-h OGTT will be formally tested for GDM because they already have a blood 
glucose measure outside normal limits. Also, HbA1c tests may be a helpful diagnostic 
tool past 12 weeks postpartum (Herrick et al., 2019). The HbA1c test does not require 
fasting and can be performed with any other blood test within the first year postpartum to 
help increase screening for T2DM. Overall, increased screening will hopefully identify 




Treatment and Management 
Treating GDM focuses on maintaining glycemic control. The results from some 
studies have been used to create treatment guidelines catered to lifestyle interventions in 
the Latinx community. Generally, GDM patients receive nutritional counseling that 
emphasizes low calorie foods. Other suggestions include nutritional counseling in 
Spanish and culturally tailored interventions (Carolan-Olah et al., 2017). How lifestyle 
interventions are culturally tailored may vary, particularly as the Latinx community 
brings together several different cultures. A survey of health educators working with 
GDM patients in the Latinx community revealed that language is a crucial element in 
making interventions culturally appropriate (Gubrium et al., 2019). The health educators 
stressed that low-quality Spanish translations and a lack of colloquial language use in 
medical literature creates barriers to care for Latinx patients. To improve the quality of 
lifestyle intervention, educational materials should have a conversational not academic 
tone. This is especially important as many health educators note that limited health 
literacy is a barrier to healthcare for Latinx patients (Gubrium et al., 2019). Another 
language barrier is the differences in regional Spanish. Although many, but not all, Latinx 
countries speak Spanish, the community is not monolithic. For instance, there are large 
differences in the Spanish spoken in the Caribbean compared with the Spanish spoken in 
South America. Health educators suggest that care should be provided using language 
that appeals to patients of different nationalities and geographical regions. 
Culturally tailored interventions are provided not only in the patient’s preferred 
language but also with nutritional counseling based on the foods that already exist in the 
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patient’s diet. For example, information on a recommended diabetic diet should include 
foods culturally specific to Latin American countries in the Caribbean and in Central 
America. Health educators found that asking Latinx patients to completely change their 
eating habits to rely heavily on foods not already a part of their diet has little success 
(Gubrium et al., 2019). One study noted that again, the Latinx community is not 
homogenous, and culturally tailored dietary recommendations for patients from one 
nationality may not apply to Latinx patients from a different nationality. For instance, a 
health educator mentioned anecdotally that a Caribbean-based diet may rely heavily on 
white rice, whereas a Central American diet may rely more on tortillas. However, 
recommendations may still be made because although dishes differ, most Latin American 
cultural foods are based heavily on starches (Gubrium et al., 2019). Trends like this allow 
physicians and medical associations to make dietary recommendations that are still 
culturally appropriate for Latinx patients as a whole.  
Diabetes management for Latinx patients should take into consideration the 
cultural importance of food. Food preparation and consumption may be considered a 
social activity (Gubrium et al., 2019). Diet adjustments must allow for normal social 
activity so that patients do not feel they need to sacrifice their culture or heritage to be 
healthy. Common foods in the Latinx community, such as white rice and tortillas, are 
starch-heavy but central to cultural meals (Gubrium et al., 2019). Recommendations for 
lifestyle changes should allow patients to continue the incorporation of culturally 
appropriate food to increase the likelihood of adherence to a diabetic diet. 
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Successful lifestyle intervention in the Latinx community should also be flexible 
in nature. Health educators working with Latinx GDM pregnancies state that the main 
stressors during pregnancy for the population are related to unstable home life, food 
insecurity, and low income. These stressors make it difficult for patients to commit to 
lifestyle changes (Gubrium et al., 2019). Patients lacking social support and with so much 
instability in their lives are often forced to move and change their phone numbers, 
making it difficult for health educators to reach them. Studies on GDM lifestyle 
intervention may choose not to include patients who cannot be reliably contacted; thus 
these patients are frequently excluded at the cost of receiving the diabetes health 
education that they need. Educators working with the Latinx community suggest 
flexibility when thinking of lifestyle intervention programs to improve the relationship 
with patients and to provide better care (Gubrium et al., 2019). The best intervention for 
patients in the Latinx community, or for any medically underserved community, should 
be flexible to account for the instability associated with a low SES.  
Certain models of lifestyle intervention have proved successful, specifically in the 
Latinx community. For instance, several OBGYN health professionals support the use of 
the Centering Pregnancy© model of group prenatal care for Latinx GDM patients 
(Centering Healthcare Institute, 2020). The Centering Pregnancy© model groups eight to 
ten patients with similar due dates for in-person sessions, each with a specific topic like 
breastfeeding or what to expect during labor and delivery. The model has been adapted to 
educate the high-risk patients for GDM through the Hispanic Centering© GDM Program 
(Schellinger et al., 2017). Upon GDM diagnosis, patients attend sessions in a group 
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setting until 36 weeks gestation and then meet individually with a health educator. The 
program focuses on the third trimester and is offered completely in Spanish.  
All patients in the Hispanic Centering© GDM Program are counseled on nutrition 
and diabetes management as well as instructed to walk at least 30 minutes a day, five 
times a week. Patients in this program were more likely to get screened for T2DM with 
an OGTT (Schellinger et al., 2017). Patient education helped in this case because patients 
usually arrive at their appointments without fasting and cannot do an OGTT. Patients in 
the Hispanic Centering© GDM Program were also less likely to need drug therapy to 
manage their GDM and were more compliant with attending prenatal appointments 
compared with Latinx patients with GDM who did not choose to participate in the 
program (Schellinger et al., 2017). Of the Latinx patients with GDM seen at the high-risk 
maternal fetal medicine clinic, 62.5% of these patients chose to participate in the 
Hispanic Centering© GDM Program, supporting the idea of group health education for 
Latinx patients with GDM (Schellinger et al., 2017). The program, as shown in Table 2, 
was proven to significantly lower birth weights and occurrences of macrosomia for 
babies born to GDM mothers that participated. Overall, the Centering© model is a useful 
tool for physicians treating GDM patients, especially racially or ethnically diverse 
patients. Additional health education provided in conjunction with standard prenatal care 







Health Outcomes for Hispanic Centering© GDM Program 
Health outcome Hispanic Centering© GDM 
Program 
Traditional GDM 













3472 ± 614 3434 ± 729 
Macrosomia (%)*  
  
16.3 19.2 
Neonatal hypoglycemia (%) 
  
5.9 1.7 
T2DM screening (%)  82.8 72.5 
  
 
Note. Table 2 values are represented as either a percentage or an average ± standard 
deviation. Health outcomes with an asterisk (*) represent significant differences in health 
outcomes between the patients in the program and the patients who received traditional 
GDM care. GDM = gestational diabetes mellitus; GWG = gestational weight gain; T2DM 
= type 2 diabetes mellitus. Adapted from (Schellinger et al., 2017).  
 
Further recommendations for managing GDM pregnancy outcomes include 
adhering to currently accepted guidelines, such as the IOM 2009 GWG guidelines. In a 
study of patients with GDM, participants with high prepregnancy BMI who had 
insufficient GWG (according to IOM guidelines) had lower rates of LGA compared with 
participants in the same BMI group that had adequate GWG (Mastella et al., 2018). In 
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order to address high rates of LGA birth weights, the IOM could consider recommending 
different GWG guidelines for patients with GDM. Given the protective effect that 
inadequate GWG has on LGA birth weights for patients of higher BMI, the IOM should 
recommend lower GWG in patients who are overweight or obese before pregnancy.  
The effect of complying with IOM recommendations suggests that dietary 
counseling and weight management may be enough to prevent neonatal complications 
with GDM pregnancies. However, researchers note that dietary counseling is often 
omitted from prenatal visits to the doctor. The ACOG currently provides 
recommendations to OBGYNs in the U.S., but it is unclear if those recommendations 
reach other health educators who may spend more time with GDM patients. 
Standardization and widespread dissemination of weight management education for 
prenatal care may be an important tool in lowering GDM rates in the Latinx community.  
As previously mentioned, the IOM guidelines are not without fault. Although the 
2009 GWG guidelines hoped to improve subject diversity, the study still predominantly 
included non-Latinx White patients with private insurance (IOM & NRC, 2009). To 
improve the health outcomes of Latinx pregnancies and other groups affected by GDM, 
medical research must include diverse patient populations in the studies. The IOM stated 
that their study had insufficient evidence to claim that their recommendations would 
apply to racially and ethnically diverse pregnancies (IOM & NRC, 2009). Unfortunately, 
this is a recurring theme in medical research centered on pregnancy. Even well-known 
pregnancy studies like the Pregnancy Risk Assessment Monitoring System claimed that 
their large-scale study had participants who were predominantly non-Latinx White and 
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currently not enrolled in Medicaid (DeSisto, 2014). Similarly, the HAPO Study 
participants were only 8.5% Latinx (Catalano et al., 2012). To best make 
recommendations on treating GDM, future studies must include Latinx patients and other 
racially and ethnically diverse patients in pregnancy research.   
 
Consideration for Further Investigation 
Another major consideration for GDM in the Latinx community is the differences 
between persons of Latinx descent and Latinx immigrants. Regardless of race and 
ethnicity, immigrant women have a higher risk of developing GDM than U.S.-born 
women. Latinx immigrants are 1.6 times more likely to develop GDM than non-Latinx 
White patients (Janevic et al., 2018). A study compared subjects born in the U.S. who 
identify as Latinx with immigrant Latinx populations. The population attributable risk 
(PAR) of GDM in U.S.-born subjects was 50% compared with the immigrant PAR of 
35.8%, both of which exceeded the occurrence of GDM in non-Latinx White subjects 
(Hedderson et al., 2010). Also, a higher BMI for immigrants is not considered an equally 
important risk factor for GDM when compared with the U.S.-born Latinx participants 
(Hedderson et al., 2010). These differences between the U.S.-born and immigrant 
populations suggest that GDM intervention targeting the Latinx community as a whole 
should not solely focus on diet counseling and weight management. 
These findings raise the question of whether the prevalence of GDM in Latinx 
pregnancies is due to genetic differences or if environmental factors also play a role. 
Studies suggest that less assimilated immigrants in the U.S. may be at a higher risk for 
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GDM, and this risk is increased for immigrants living within ethnic enclaves (Janevic et 
al., 2018). However, the length of time spent in the U.S. is positively associated with 
increased BMI for Asian and Latinx immigrants, although BMI is not considered as much 
of a risk factor for GDM in immigrants (Hedderson et al., 2010; Janevic et al., 2018). The 
association with assimilation and risk factors for GDM that is evident in Latinx 
immigrants points to the importance of lifestyle and environmental factors in contributing 
to higher rates of GDM. Further GDM studies should explore what causes the differences 
between immigrant and non-immigrant groups to determine if social factors like 
education level or SES can outweigh genetic predisposition to GDM.  
Future research should also consider the effect of intersecting identities when 
grouping participants for medical research. For example, Afro-Latinx participants in 
research are often forced into either the racial Black group or the ethnic Latinx group for 
maintaining data that can be easily quantified. Some studies will even list participants of 
more than one racial/ethnic identity into the “other” category (Herrick et al., 2020). This 
method of classification does a disservice to patients who may belong to two groups that 
both have an increased risk for developing GDM. Studies should consider more specific 





Gestational diabetes plagues Latinx pregnancies at a much greater extent than 
other racial or ethnic groups. This thesis evaluated the relationship between GDM and the 
Latinx community to understand why this population is disproportionately affected. 
Moreover, the effects of GDM on maternal and fetal outcomes were analyzed to 
emphasize the importance of GDM prevention and treatment. After examining the current 
standards of care for Latinx GDM pregnancies, this review offered evidence-based 
recommendations for improving Latinx screening, treatment, and management of GDM. 
Several studies indicate greater occurrences of GDM in the Latinx community 
that can be attributed to not only genetic factors but also environmental factors 
(Hedderson et al., 2010). Although several genes linked to GDM development have been 
studied in the Latinx community, social factors likely play a role in the incidence as well. 
Furthermore, members of the Latinx community with GDM also develop T2DM at 
greater rates (Gubrium et al., 2019). However, current pregnancy studies often do not 
recruit enough Latinx patients to be able to apply significant associations to the most 
affected population. For this reason, any future studies on GDM should appropriately 
address the disproportionate occurrence of GDM among Latinx pregnancies.  
 Some GDM risk factors are predominant health issues in the Latinx community. 
The most strongly associated risk factors for GDM are increased prepregnancy BMI and 
excessive GWG (Moore Simas et al., 2019). Both of these risk factors are major health 
issues seen in Latinx pregnancies (Carolan-Olah et al., 2017). Environmental factors may 
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influence the likelihood of these risk factors because Latinx people in the U.S. may be 
driven to more calorie-dense and processed foods that are more accessible in lower 
income areas. Also, GDM is more prevalent with increased parity, and Latinx families 
have higher birth rates than other racial and ethnic groups (Moore Simas et al., 2019). 
Therefore, it is clear that the Latinx community has a higher rate of GDM occurrences 
because this population leads in several apparent causes of GDM. 
 GDM can affect several organ systems and have serious long-term health 
consequences. One of the major concerns for maternal health in GDM pregnancies is the 
metabolic health of the mother postpartum. Almost half of GDM pregnancies lead to the 
development of T2DM (Khan et al., 2019). Latinx pregnancies are even more likely to 
develop T2DM when complicated by GDM (Gubrium et al., 2019). The early onset of 
diabetes, or MODY, for patients with GDM can lead to experiencing more diabetes 
complications in their lifetime. In addition, Latinx pregnancies with GDM are more likely 
to have recurrent GDM in subsequent pregnancies, increasing the risk for further 
complications (Carolan-Olah et al., 2017). Similarly, GDM increases the risk for adverse 
pregnancy outcomes like maternal hypertension and unplanned cesarean section 
(Carolan-Olah et al., 2017). Overall, GDM increases the risk for pregnancy and 
postpartum complications to maternal health.  
 The fetus can be particularly impacted by GDM because metabolic programming 
is known to begin in utero. Several studies have correlated maternal hyperglycemia with 
fetal hypoglycemia (Chen et al., 2015). The long-standing Pedersen hypothesis states that 
maternal hyperglycemia is associated with not only fetal hypoglycemia but also fetal 
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hyperinsulinemia, growth, and adiposity (Pedersen, 1971). Modern studies, most notably 
the HAPO Study, have supported the linear relationship proved by the Pedersen 
hypothesis (Catalano & Hauguel-De Mouzon, 2011). The HAPO Study even went further 
to show how the Pedersen hypothesis applies to not only clinically diagnosed GDM 
pregnancies but also pregnancies that began at an overweight BMI or have high blood 
glucose levels not technically considered diabetic. The strong relationship between the 
variables in the Pedersen hypothesis is important perinatally and affects the lifelong 
health of the fetus.  
 Current treatment for GDM across all patients focuses on reaching and 
maintaining glycemic control. The first strategy for treating GDM is lifestyle 
modification, a practice that is notably effective among Latinx pregnancies (Herrick et 
al., 2020). When building healthy eating and exercise habits with a diabetes health 
educator, Latinx patients are able to maintain glycemic control without the need for 
pharmacologic intervention (González-Quintero et al., 2008). Studies have even 
identified that lifestyle intervention can be successful in many patients, but those with 
extremely high HbA1c values upon GDM diagnosis will eventually require 
pharmacological treatment (González-Quintero et al., 2008). This finding is significant 
because it can help patients with more severe GDM reach healthier blood glucose levels 
for pregnancy in a shorter time. In fact, pharmacological treatment is actually noted to 
have several benefits, including lower GWG and less pregnancy complications, which 
improve GDM maternal health overall (Hartling et al., 2013). Pharmacological treatment 
can even improve fetal outcomes (Carlson et al., 2020). Another way to improve GDM 
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health outcomes is to increase T2DM screening postpartum. Currently, screening rates 
for T2DM postpartum are relatively low and indeed lower if only considering the 
screening deemed appropriate by the ACOG (Hale et al., 2012). Screening rates are 
remarkably low, especially for lower income patients who are often the patients most at 
risk for developing T2DM. To truly improve the current standards of care for GDM, the 
ACOG should issue guidelines emphasizing the therapies that help the most affected 
communities.  
 As previously mentioned, screening rates for GDM and T2DM postpartum are 
generally low. Researchers overwhelmingly support the use of diagnostics besides the 
standard 2-h OGTT to increase the number of GDM patients who are actually diagnosed 
and treated (Metzger et al., 2010). The ADA accepts more common and convenient tests 
like FPG and HbA1c values as preliminary diagnostic tools to identify which patients 
should truly be screened for GDM using the standard test. Further advancements in GDM 
screening should take advantage of the known biomarkers for GDM. Molecular markers 
such as 8-oxodG and 8-OHdG can be used to identify GDM from a routine blood 
analysis (Urbaniak et al., 2020). Some biomarkers may be particularly effective in some 
of the predominantly affected populations. Several lipid signatures are proved to exist in 
GDM patients, particularly Latinx and Asian patients (Khan et al., 2019). Early detection 
may be key to decreasing the effect of adverse GDM outcomes and preventing the 
development of T2DM postpartum. 
 Other advancements in GDM care point to the importance of patient education. 
Diet and overall diabetic health education are associated with increasing postpartum 
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T2DM screening and better health outcomes (Hale et al., 2012). In particular, group 
diabetes education and support have proved to be an effective tool for improving health 
outcomes in Latinx GDM pregnancies (Gubrium et al., 2019). Health educators have 
emphasized the importance of culturally tailored diet and exercise recommendations. 
Other social factors for diabetes health educators to consider when working with GDM 
patients include limited health literacy, food insecurity, and financial insecurity. A 
particularly successful model for Latinx GDM patients is the Hispanic Centering© GDM 
Program (Schellinger et al., 2017). This Latinx-specific group GDM lifestyle intervention 
is shown to improve fetal health outcomes by decreasing average birth weights and 
occurrences of macrosomia. Modern recommendations from the IOM or ACOG should 
take into account the success of these methods in Latinx populations.  
 Although this thesis was able to identify key recommendations for improving 
Latinx GDM care, it did have its limitations. This thesis was limited in its analysis of 
GDM in the Latinx community because only more recent studies include patients from 
this population. Still, the Latinx community is grossly underrepresented in most 
pregnancy research studies (DeSisto, 2014). The discrepancy between the percentage of 
GDM pregnancies that are Latinx and the percentage of subjects in pregnancy studies that 
are Latinx do not allow for strong statistical analysis of results so that they can be applied 
to Latinx patients. Moreover, even the studies used by the IOM to develop guidelines for 
GWG, one of the main determinants of GDM development, stated that there was 
insufficient evidence to apply the findings to patients who are not non-Latinx White 
(IOM & NRC, 2009). The IOM should include studies that appropriately represent the 
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demographics in the U.S. so that guidelines can be formulated that apply to all 
populations. All recommendations should be based on studies with adequate 
representation to form statistically significant conclusions. 
In the future, the Latinx community should be at the forefront of 
recommendations made by healthcare professionals on GDM. For better treatment of 
Latinx patients with GDM, Latinx subjects should be included in GDM research. 
Institutional recommendations by the ACOG for GDM standards of care should consider 
therapies that are successful in treating Latinx patients. For instance, the Hispanic 
Centering© GDM Program should be considered a standard treatment option for Latinx 
patients diagnosed with GDM by their OBGYN. This particular program and the original 
Centering Pregnancy© model have wide applications for improving overall pregnancy 
outcomes (Centering Healthcare Institute, 2020). Treatments for GDM should be 
considered efficacious based on their success in the most affected groups.  
This thesis focused on the Latinx community; however, the same principles could 
apply to other populations. For example, the Asian community, much like the Latinx, is 
not a monolith and represents the second most affected group by GDM (DeSisto, 2014). 
There exists enough cultural ties between the two groups for the findings of this thesis to 
be applied to the Asian community as well. For instance, the social and cultural aspects 
of eating habits, along with the prevalence of starches in the diet, allow many of the 
lifestyle modifications for Latinx patients to also apply to Asian patients. The 
communities even share some of the same biomarkers for GDM (Khan et al., 2019). 
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Hopefully, future research will aim to alleviate the disparity in pregnancy healthcare for 
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